Prolactin, humanCatalogue number: PR105
The antibody is suitable for the detection of prolactin producing cells and for the differentiation from other hormone producing cells in the pituitary and pituitary adenoma. Prolactin is the luteotropic hormone, which is synthesized in the pituitary gland and is released into the blood stream to stimulate the corpus luteum to produce progesterone. During perinatal phase prolactin together with steroid hormones is responsible for the structural changes of the mammary glands and the milk production. Abnormal proliferation of prolactin cells may lead to prolactinoma, which can cause galactorrhoe and infertility in women. Human prolactin, no cross-reactivity with hPL (placental lactogen) and hGH (growth hormone) in RIA and ELISA.
Immunogen: Purified hPRL
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.
Purification Method: Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.
Concentration: 100 µg/ml
Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).
Species Reactivity: Human
Incubation Time: 60 min at RT
Working Concentration: (liquid conc.) 1:50
Pre-Treatment: No protease pre-treatment required
Positive Control: Pituitary
*These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals. ** The preservative sodium azide is known to be poisonous and potentially hazardous to health. It should be handled only by trained staff. Despite of the product's low azide concentration it must be handled with care. Dispose according to regional rules!
1. Franks S., Murray M.A.F., Jequier A.M., Steele S.J., Nabarro J.D.N., and Jacobs H.S. (1975) Incidence and significance of hyperprolactinaemia in women with amenorrhoea. Clin. Endocrinol. 4; 597-607. 2. Schott W., Buchfeder M., Fahlbusch R., Herzog A., von Werder K., Kovacs K. (1997) Unusual morphology of a malignant prolactinoma undergoing neuronal differentiation. Exp. Clin. Endocrinol. Diabetes 105 (Suppl. 1) Abstract p039 p. 64.